SB 1047 directs the state department to build a system to track incidence and prevalence of neurodegenerative diseases in California and to designate those diseases as reportable. The measure requires hospitals, clinics, physicians and other providers to report cases in a department-prescribed format and gives the department access to provider records when needed.
The bill matters because it shifts identifiable clinical data into a centralized public-health registry, creates specific enforcement tools (civil penalties and cost-recovery when the state steps in), and exempts program contracts from a portion of the Public Contract Code — all of which affect providers, public‑health researchers, and patient privacy governance at the state level.
At a Glance
What It Does
Creates a departmental program to collect incidence and prevalence data for neurodegenerative diseases, requires reporting of all cases diagnosed or treated in California, and establishes confidentiality for collected information. It authorizes the department and its representatives to access provider records and recover costs when providers fail to report in the required format.
Who It Affects
Hospitals, outpatient clinics, physicians and surgeons, other health care facilities and their health information systems; the state department that will run the registry; researchers and advocacy groups that rely on disease surveillance; and patients whose identifiable medical records may be accessed.
Why It Matters
The bill centralizes identifiable surveillance data for conditions like ALS, Alzheimer’s, FTD, multiple sclerosis and Huntington’s disease, creating new compliance obligations and potential privacy risks while giving the state fast-track contracting authority to stand up the program — a combination that changes how California collects and governs clinical data for long-term neurological conditions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 1047 orders the unnamed state department to set up a system that tracks how often Californians are diagnosed with or treated for neurodegenerative diseases and to determine how common those diseases are across the state. The bill lists several illustrative conditions — ALS, frontotemporal degeneration, Alzheimer’s and related dementias, multiple sclerosis, and Huntington’s disease — and gives the department authority to designate which diagnoses will be reportable.
The statute frames the collected dataset as confidential but also creates explicit procedures for the department to obtain the underlying medical records when necessary.
Under the bill, providers must submit each case in a format the department prescribes. If a hospital or facility does not provide data in that format, the department’s authorized representative may retrieve the necessary information directly from the provider and then file the report.
When the department steps in to extract and submit records because of provider noncompliance, the provider must reimburse the state for costs the department incurs to access and report the information.The bill goes further on record access: it requires hospitals, clinicians, clinics, and any entity providing diagnosis or treatment to grant the department or its authorized representative access to all records that would identify a case or establish disease characteristics, treatments, or medical status. Willful refusal to allow access is subject to daily civil penalties, with collected fines deposited into the General Fund.
Finally, the director may run the program with outside contracts or grants, and those awards are explicitly exempted from Part 2 of Division 2 of the Public Contract Code; the program only operates to the extent funding is available.
The Five Things You Need to Know
The department must notify associations representing physicians and hospitals and the Medical Board of California at least 90 days before it begins requiring reporting.
Willful refusal to grant the department access to identifiable records triggers a civil penalty of up to $500 per day for each day access is denied.
If a hospital or facility fails to report in the prescribed electronic or other format, the department’s authorized representative may access the provider’s records and the provider must reimburse the department for the costs of that access and reporting.
The director may enter into contracts, grants, or funding agreements to run the program, and those awards are exempt from Part 2 (commencing with Section 10100) of Division 2 of the Public Contract Code.
All information collected under the program is labeled as confidential information by the bill, but the statute simultaneously authorizes access to identifiable medical records for the department and its authorized representatives.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
State duty to collect incidence data
This clause creates the baseline statutory duty: the department must collect data on the incidence of neurodegenerative disease in California. Practically, that triggers the administrative planning that will define scope, staffing, and data standards. It creates a legal obligation rather than a discretionary study, which gives the department a clear statutory hook to build and operate the registry once funded.
Registry creation and designation of reportable diseases
The department must establish a system for collecting information to determine incidence and prevalence and may designate diseases as required to be reported. That dual phrasing — build the system and designate reportable diseases — gives the department both technical and rulemaking levers: it will set what diagnoses and case definitions are in scope, and it sets the administrative requirement that cases diagnosed or treated in California be reported.
Advance notice to clinicians and Medical Board
The department must publish notice on its website and notify physician and hospital associations and the Medical Board of California at least 90 days before requiring reporting. That creates a short but mandatory lead time for stakeholder outreach and system onboarding; it also creates an administrative timeline that providers and EHR vendors will use to schedule technical work.
Provider reporting obligation and state backstop
Providers — hospitals, facilities, physicians and other health care providers — must report each case in the format the department prescribes. If a facility fails to comply with the prescribed format, the bill authorizes an authorized representative to access the provider data and file the report, and it requires the provider to reimburse the state for the department’s costs to retrieve and submit that data. That reimbursement clause creates a cost-recovery mechanism but also the potential for intergovernmental disputes over what constitutes reasonable retrieval costs.
Access to identifiable records and enforcement
This provision compels providers to grant the department or an authorized representative access to records that identify a case or establish disease characteristics, treatment, or medical status. The bill treats willful refusal as a daily civil violation with penalties up to $500 per day and directs that fines be deposited into the General Fund. Mechanically, the provision gives the department direct access to identifiable clinical data and an enforcement tool to secure compliance.
Confidentiality labeling
The statute designates collected information as confidential 'except as otherwise provided in this chapter' and refers to it as 'confidential information.' That labeling will interact with state and federal privacy laws and with any later statutory exceptions the department creates; it does not by itself define permitted disclosures or analytic uses of the data.
Program governance and procurement exemption
The director controls the program and may enter into contracts, grants, or agreements needed to operate it. Crucially, awards are exempted from a specific part of the Public Contract Code (Part 2, commencing with Section 10100), which removes some competitive procurement requirements; the program is also explicitly contingent on available funding. Those mechanics speed contracting but reduce the usual procurement oversight on vendor selection and contract terms.
Scope: what counts as a neurodegenerative disease
The bill provides a nonexclusive list of conditions — ALS, frontotemporal degeneration (FTD), Alzheimer’s disease and other dementias, multiple sclerosis, and Huntington’s disease — and allows the department flexibility to include other neurodegenerative diagnoses. The nonexclusive phrasing means the registry can expand over time, which affects future reporting scope and technical design for disease-specific data elements.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State public‑health planners and epidemiologists — They gain a centralized, comprehensive dataset to measure incidence and prevalence trends and to target resource allocation and research priorities.
- Clinical and academic researchers focused on neurodegenerative diseases — They get a richer, population-level surveillance resource that can support translational studies, registry-based recruitment, and natural history analyses.
- Patient advocacy organizations — Improved surveillance can strengthen advocacy for funding, services, and clinical trial access by producing state-level burden estimates and geographic patterns.
Who Bears the Cost
- Hospitals and outpatient clinics — They must implement reporting workflows, map EHR data to the department’s prescribed format, and may face reimbursement obligations if the department retrieves records on their behalf.
- Small and rural providers and safety‑net clinics — Limited IT and staff capacity may make the reporting burden disproportionately expensive, forcing either outside vendor work or diverting clinical staff time.
- The administering department — It must build the registry, define data standards, manage authorizations to access identifiable records, and stand up contracting arrangements; those start‑up and ongoing costs fall on the agency and depend on appropriations.
Key Issues
The Core Tension
The bill tries to reconcile two legitimate goals — obtaining comprehensive, identifiable surveillance data necessary to measure and respond to neurodegenerative diseases, and protecting patients’ privacy and limiting burdens on clinical providers — but it does so by granting broad access and enforcement powers to the department while leaving privacy safeguards, funding for provider compliance, and procurement oversight under-specified. That trade-off — more complete public‑health intelligence at the cost of provider burden and privacy risk — is the statute’s central dilemma.
The bill sets up a public‑health registry that is simultaneously labeled 'confidential' and authorized to include identifiable clinical records with compelled access. That creates an unresolved statutory intersection with state and federal health privacy frameworks (for example, the Health Insurance Portability and Accountability Act and California health privacy laws): the statute does not specify how the department will reconcile mandatory disclosure to the registry with HIPAA’s standards for protected health information, nor does it describe de‑identification standards, data retention limits, or secondary-use rules for researchers and vendors.
Practically, the requirement that providers report in a 'format prescribed by the department' delegates substantial technical design authority to the agency but leaves critical implementation questions open: what fields will be required, how will EHR vendors be asked to deliver data, what validation and error‑handling processes will exist, and how will smaller providers meet the technical bar without state-funded assistance. The procurement exemption speeds vendor selection but reduces competitive safeguards, increasing the risk that early contracts could embed costly or nonportable data standards.
Finally, the cost‑recovery clause that requires providers to reimburse the department when it retrieves data creates an odd incentive dynamic — it could motivate the department to remediate noncompliance by doing the work itself, then billing providers, rather than building provider‑friendly reporting interfaces or offering implementation support.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.